![David Altreuter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Altreuter worked as Formulation Director at Selecta Biosciences, Principal at Acusphere, Inc. and Alnylam Pharmaceuticals, Inc., and Vice President-CMC at Quiet Therapeutics Ltd. He received an undergraduate degree from Princeton University and a doctorate degree from the University of California, Berkeley.
| Bedrijven | Functie | Einde |
|---|---|---|
| ACUSPHERE, INC. | Corporate Officer/Principal | - |
| CARTESIAN THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Quiet Therapeutics Ltd.
 Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 6 |
|---|---|
Acusphere, Inc.
 Acusphere, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes drugs | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Develops targeted immunotherapies and vaccines to treat and prevent diseases | Health Technology |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quiet Therapeutics Ltd.
Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
